Mastodon

Quatran® xylo (Spray, Drops) Instructions for Use

ATC Code

R01AA07 (Xylometazoline)

Active Substance

Xylometazoline (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Vasoconstrictor drug for topical use in ENT practice

Pharmacotherapeutic Group

Drugs for the treatment of nasal diseases; decongestants and other drugs for topical use; sympathomimetics

Pharmacological Action

Vasoconstrictor for topical use in ENT practice. Alpha-adrenomimetic. When applied to the mucous membranes, it causes constriction of the blood vessels of the nasal mucosa, thereby eliminating swelling and hyperemia of the nasal mucosa, and restores the patency of the nasal passages. In rhinitis, it facilitates nasal breathing.

Pharmacokinetics

When applied topically, it is practically not absorbed; plasma concentrations are so low that they cannot be determined by modern analytical methods.

Indications

To reduce swelling of the nasopharyngeal mucosa and discharge in acute allergic rhinitis, acute respiratory infections with symptoms of rhinitis, sinusitis, hay fever, otitis media; preparation of the patient for diagnostic procedures in the nasal passages.

ICD codes

ICD-10 code Indication
H66 Suppurative and unspecified otitis media
J00 Acute nasopharyngitis (common cold)
J01 Acute sinusitis
J06.9 Acute upper respiratory infection, unspecified
J30.1 Allergic rhinitis due to pollen
J30.3 Other allergic rhinitis (perennial allergic rhinitis)
J32 Chronic sinusitis
Z51.4 Preparatory procedures for subsequent treatment or examination, not elsewhere classified
ICD-11 code Indication
AA9Z Unspecified suppurative otitis media
CA00 Acute nasopharyngitis
CA01 Acute rhinosinusitis
CA07.0 Acute upper respiratory tract infection of unspecified site
CA08.00 Allergic rhinitis due to pollen
CA08.03 Other allergic rhinitis
CA0A.Z Chronic rhinosinusitis, unspecified
QB9A Preparatory procedures for subsequent treatment

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer intranasally only. Strictly adhere to the age-specific dosing instructions. Do not exceed the recommended frequency or duration of use.

For the nasal spray (0.1% solution): Adults and children aged 12 years and older: administer one spray into each nostril. Repeat this dose up to three times per day as needed. Maintain an interval of at least six hours between applications.

For the nasal drops (0.05% solution): Children aged 2 to 6 years: administer one drop into each nostril. Repeat this dose up to two times per day. Children aged 6 to 12 years: administer one to two drops into each nostril. Repeat this dose up to two times per day.

The maximum duration of continuous treatment is seven days. Prolonged use can lead to medicinal rhinitis and rebound congestion. If symptoms persist beyond one week, discontinue use and consult a physician.

For diagnostic procedures, a single application is typically sufficient. Follow the specific instructions provided by the healthcare professional.

Before initial use, prime the spray pump by pressing it several times. To administer, keep the head upright, insert the tip into the nostril, and spray towards the outer wall while breathing in gently through the nose.

Adverse Reactions

From the immune system uncommon – hypersensitivity reactions (angioedema, skin rash, itching).

From the digestive system rare – nausea, vomiting.

From the nervous system: rare – headache; very rare – insomnia, anxiety, fatigue, hallucinations and convulsions (mainly in children).

From the organ of vision very rare – blurred vision.

From the cardiovascular system rare – palpitations, increased blood pressure, tachycardia; very rare – arrhythmia.

Local reactions common – irritation and/or dryness of the nasopharyngeal mucosa, burning and paresthesia of the nasal mucosa, sneezing, hypersecretion of the nasal mucosa; uncommon – swelling of the nasal mucosa, nosebleeds, withdrawal syndrome. Increased swelling of the nasal mucosa (reactive hyperemia) is possible.

Contraindications

Hypersensitivity to xylometazoline; atrophic rhinitis, thyrotoxicosis; inflammatory diseases of the skin or mucous membrane of the nasal vestibule; condition after transsphenoidal hypophysectomy; patients with severe cardiovascular diseases (e.g., coronary artery disease, angina pectoris, tachycardia, arterial hypertension, severe atherosclerosis); patients with a history of surgical interventions on the meninges; patients receiving MAO inhibitors or other drugs that can cause increased blood pressure; patients with increased intraocular pressure, especially with angle-closure glaucoma; during therapy with tricyclic and tetracyclic antidepressants, other topical vasoconstrictors (decongestants); pregnancy; pediatric age – depending on the dosage form.

With caution patients with hypersensitivity to adrenomimetics, accompanied by symptoms of insomnia, dizziness, arrhythmia, tremor, increased blood pressure; patients with pheochromocytoma, porphyria; patients with endocrine diseases (e.g., hyperthyroidism, diabetes mellitus); patients with prostatic hyperplasia; during lactation (breastfeeding).

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy. During lactation, use is possible only as prescribed by a doctor, after a thorough assessment of the ratio of the intended benefit for the mother to the potential risk for the child. Exceeding the recommended doses is not allowed.

Pediatric Use

Use in children is possible according to indications, in age-appropriate recommended doses and dosage forms. It is necessary to strictly follow the instructions in the drug labels for xylometazoline regarding contraindications for the use of specific dosage forms of xylometazoline in children of different ages. Recommended doses should not be exceeded in children.

Geriatric Use

Recommended doses should not be exceeded in elderly patients.

Special Precautions

Long-term use (more than 7 days) and overdose of sympathomimetics with a decongestant effect can lead to reactive hyperemia of the nasal mucosa. As a result, nasal breathing difficulty occurs, which leads to the patient starting to use xylometazoline repeatedly or even constantly. This can lead to chronic swelling (medicinal rhinitis), and ultimately even to atrophy of the nasal mucosa (ozena).

In milder cases, to improve the patient’s condition, it is possible to first stop the administration of the sympathomimetic into one nostril, and after the complaints decrease, continue to administer it into the other nostril, in order to at least partially ensure nasal breathing.

Recommended doses should not be exceeded, especially in children and elderly patients.

Effect on the ability to drive vehicles and mechanisms

With long-term treatment or when using xylometazoline in higher doses, the possibility of its systemic action cannot be excluded. In case of systemic side effects, it is necessary to refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Drug Interactions

Enhancement of the systemic action of xylometazoline is possible with simultaneous use of MAO inhibitors and tricyclic antidepressants. Simultaneous use of xylometazoline with tetracyclic antidepressants, other topical vasoconstrictors (decongestants), as well as other drugs that increase blood pressure is incompatible.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Forms

Bottle OTC Icon Quatran® xylo Nasal drops 0.1%: dropper tubes 10 ml, 15 ml or 20 ml; ampoule 10 ml 1 or 2 pcs., 15 ml or 20 ml 1 pc.
Nasal drops 0.05%: dropper tubes 10 ml, 15 ml or 20 ml

Dosage Form, Packaging, and Composition

Nasal drops as a colorless or yellowish, clear liquid.

1 ml
Xylometazoline hydrochloride 1 mg

Excipients: sea water – 400 mg, potassium dihydrogen phosphate (potassium phosphate monobasic) – 0.45 mg, purified water – up to 1 ml.

10 ml – dropper tubes (1) – cardboard boxes.
15 ml – dropper tubes (1) – cardboard boxes.
20 ml – dropper tubes (1) – cardboard boxes.
10 ml – ampoules (1) complete with a bottle – cardboard boxes.
10 ml – ampoules (2) complete with a bottle with a spray nozzle – cardboard boxes.
15 ml – ampoules (1) complete with a bottle – cardboard boxes.
20 ml – ampoules (1) complete with a bottle – cardboard boxes.


Nasal drops as a colorless or yellowish, clear liquid.

1 ml
Xylometazoline hydrochloride 0.5 mg

Excipients: sea water – 400 mg, potassium dihydrogen phosphate (potassium phosphate monobasic) – 0.45 mg, purified water – up to 1 ml.

10 ml – dropper tubes (1) – cardboard boxes.
15 ml – dropper tubes (1) – cardboard boxes.
20 ml – dropper tubes (1) – cardboard boxes.

Marketing Authorization Holder

PFKO-1, LLC (Russia)

Manufactured By

Obnovlenie Pfc, JSC (Russia)

Dosage Forms

Bottle OTC Icon Quatran® xylo Metered-dose nasal spray 45 mcg/dose
Metered-dose nasal spray 90 mcg/dose

Dosage Form, Packaging, and Composition

Metered-dose nasal spray

1 dose
Xylometazoline (as hydrochloride) 45 mcg

(150 doses) – bottles – cardboard boxes – Over-the-Counter
(190 doses) – bottles – cardboard boxes – Over-the-Counter
(95 doses) – bottles – cardboard boxes – Over-the-Counter


Metered-dose nasal spray

1 dose
Xylometazoline (as hydrochloride) 90 mcg

(150 doses) – bottles – cardboard boxes – Over-the-Counter
(190 doses) – bottles – cardboard boxes – Over-the-Counter
(95 doses) – bottles – cardboard boxes – Over-the-Counter

TABLE OF CONTENTS